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The SARS-CoV-2 pandemic has had a global impact and has put scientific
endeavour in the spotlight, perhaps more than any previous viral outbreak.
Fortuitously, the pandemic came at a time when decades of research in mul-
tiple scientific fields could be rapidly brought to bear, and a new generation of
vaccine platforms was on the cusp of clinical maturity. SARS-CoV-2 also
emerged at the inflection point of a technological revolution in macromolecu-
lar imaging by cryo-electron microscopy, fuelled by a confluence of major
technological advances in sample preparation, optics, detectors and image
processing software, that complemented pre-existing techniques. Together,
these advances enabled us to visualize SARS-CoV-2 and its components
more rapidly, in greater detail, and in a wider variety of biologically relevant
contexts than would have been possible even a few years earlier. The resulting
ultrastructural information on SARS-CoV-2 and how it interacts with the host
cell has played a critical role in the much-needed accelerated development of
COVID-19 vaccines and therapeutics. Here, we review key imaging modalities
used to visualize SARS-CoV-2 and present select example data, which have
provided us with an exceptionally detailed picture of this virus.1. Background
COVID-19 grew to pandemic scale with alarming speed and has continued to
claim a heavy toll. However, the advent of the pandemic in late 2019 was fortui-
tous in more ways than one. A new generation of vaccine platforms was on the
cusp of clinical maturity, making it possible for multiple highly effective vaccines
to be developed and approved within a year of the outbreak. Perhaps just as
importantly, SARS-CoV-2 emerged at the inflection point of a technological revo-
lution in macromolecular imaging by cryo-electron microscopy (cryo-EM), fuelled
by a confluence of major advances in sample preparation, optics, detectors and
image processing software for electron microscopy [1–3]. Together, these advances
enabled us to visualize the molecular structure of SARS-CoV-2 and its com-
ponents more rapidly, in greater detail, and in a wider variety of biologically
relevant contexts than would have been possible even a few years earlier. The
resulting wealth of ultrastructural information on SARS-CoV-2 and how it inter-
acts with the host cell played a critical role in the remarkable and much-needed
acceleration in the development of COVID-19 vaccines and therapeutics. Here,
we review the key imaging modalities used to visualize SARS-CoV-2 and present
select example data that have provided us with an exceptionally detailed picture
of SARS-CoV-2 on a wide range of scales at every stage of the viral life cycle.2. The resolution spectrum
Microscopes have been used to image viruses since viruses were discovered in
the late nineteenth century [4], but only in the last decade or so have
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Figure 1. Recent technological advances have allowed us to image SARS-CoV-2 and its components on a continuous resolution spectrum up to the near-atomic
scale. From left to right: a schematic of spike protein on the surface of cells as it would appear if visualized by fluorescent light microscopy; a schematic of a SARS-
CoV-2 virion as it would appear if visualized by cryo-electron tomography; a cryo-EM reconstruction of the spike protein trimer (EMD-21374); a model based on the









Figure 2. SARS-CoV-2 and the cell. (a) Electron microscopy plays an important confirmatory role in diagnosis and determining subcellular localization. A false-colour
transmission electron micrograph of SARS-CoV-2 isolated from a patient. Coronaviruses are approximately 80–120 nm in diameter [7]. (b) A false-colour scanning
electron micrograph of an apoptotic cell (green) infected with SARS-CoV-2 isolated from a patient. The virions can be observed as small yellow spheres. (a) and (b)
are adapted from images of ‘Novel Coronavirus SARS-CoV-2’ published by NIAID and licensed under CC BY 2.0 [8,9]. To view a copy of this license, visit https://
creativecommons.org/licenses/by/2.0/. (c) Fluorescence microscopy can show subcellular localization. Co-localization of FLAG-tagged SARS-CoV-2 protein Orf6 with
nuclear pore complex protein Nup358 in HEK293T cells as imaged by stimulated emission depletion (STED) super-resolution microscopy. Scale bar in the left-most







technological advances in electron microscopy allowed us to
image viruses on a continuous resolution spectrum. With
dimensions smaller than the wavelength of visible light,
viruses could not be visualized directly until the invention
of the electron microscope in the 1930s [5,6] (figure 1).
Since then, electron microscopy has been the method of
choice for identifying viruses, based on their size, shape,
ultrastructural features and tissue distribution. Our first
glimpses of SARS-CoV-2 were in electron micrographs
taken within weeks of the outbreak (figure 2) [11].
The images derived from electron microscopy are often
noisy, making the features contained therein appear fuzzyand indistinct. This effect can be compounded by the treat-
ments that samples must be subjected to prior to imaging in
a conventional transmission electron microscope. Chemical fix-
ation, use of contrast agents (e.g. uranyl acetate), drying and
embedding of the sample in plastic resin limit the imaging res-
olution and distort the sample, yielding results that fall short
of the molecular detail needed to be useful in vaccine and anti-
viral drug design. X-ray crystallography of viral proteins,
macromolecular assemblies and occasionally entire viruses
can provide the necessary resolution but requires the object
of interest to be crystallized. In practice, this limits crystallo-





3soluble and relatively small (rarely larger than 200 kDa)
macromolecules. The irregular, non-spherical shape of
SARS-CoV-2 virions, therefore, precludes crystallization.
Up until the mid-2010s, in most cases, the limitations
of these techniques left a large gap in achievable imaging
resolutions between conventional transmission electron
microscopy (with resolutions on the order of nanometres)
and X-ray crystallography (with resolutions on the order of
angstroms). For the most part, determining the structure of
an entire virion, alone or in the context of a host cell, remained
inaccessible to high resolution structure determination by any
method. This began to change with the Nobel-prize-winning
development by Dubochet and colleagues [12] of cryogenic
vitrification of aqueous samples, including viruses, for
cryo-EM imaging. These early cryo-EM micrographs were
essentially free of preservation artefacts but still suffered from
blurring and poor signal-to-noise ratios. Additional develop-
ments, most notably direct electron detectors, maximum
likelihood image classification and averaging algorithms, and
improved tomographic reconstruction and subtomogram aver-
aging (STA) algorithms, which became widely available from
2013 onwards, really brought the field to the fore [1–3].
These advances ushered in a new era in structural biology in
which the structures of large asymmetric macromolecular
assemblies can now be reconstructed at a resolution sufficient
to build atomic models (between 0.1 nm and 1 nm resolution).
While the use of contrast reagents and conventional electron
microscopy on chemically fixed samples continues to be the
method of choice for rapid identification of viruses, particu-
larly, within infected cells or tissues, cryo-EM extends our
ability to obtain high-resolution information of entire viruses
and macromolecular assemblies that cannot be crystallized.
When SARS-CoV-2 emerged, these tools had matured, allow-
ing them to be rapidly applied to the virus and its
components on a continuous resolution spectrum, through a
combination of conventional electron microscopy, cryo-EM
and X-ray crystallography (figure 1). The snapshots from
these structural studies have been provided a more dynamic
biological context through the use of light microscopy, which
can be used to track and identify viruses in real-time as they
move through the host cell (figure 2).3. Finding and tracking SARS-CoV-2 in the cell
Transmission electron microscopy (TEM) of tissue or fluid
samples has historically played a key role in the identification
of new viruses. SARS-CoV-2 was first imaged by TEM within
weeks of the initial outbreak (figure 2a) [11]. Micrographs pro-
vided important visual confirmation of sequencing data that
the new virus, displaying the prototypic ‘corona’ of glyco-
proteins, was a coronavirus. TEM also supported biochemical
data suggesting that virus entry can occur at the plasma mem-
brane or via endosomes [13–15]. Scanning electron microscopy
(SEM) of infected cells showed large numbers of virus particles
released from a single cell indicating that infection was acute
and highly productive (figure 2b). However, these TEM and
SEM micrographs alone cannot provide the molecular detail
needed to understand the specific protein–protein interactions
at the heart of the biological processes essential to the virus
life cycle; for example, how SARS-CoV-2 recognizes host cells
or how antibodies neutralize the virus. Moreover, these
images are static, yielding no clues about the timescales ofvirus-cell entry, establishment of replication sites—‘virus fac-
tories’, and emergence of newly replicated virions from the cell.
Electron microscopy samples must be imaged in a vacuum
to prevent scattering of the electron beam, thus making it
impossible to study the dynamics of biological processes in
living specimens. By contrast, light microscopy can be per-
formed on live cells, allowing for example, tracking of
fluorescently labelled viruses in real-time as they travel through
the cell. Despite its lower imaging resolutions, light microscopy
powerfully complements electron microscopy by providing a
time dimension. Moreover, the use of genetically or chemically
encoded fluorescent labels allows targets of interest, such as
viral proteins, to be identified among the tens of thousands
of other proteins that make up the cell (figure 2c). Fluorescence
microscopy of virus-infected cells has been used to identify
possible cell entry pathways for SARS-CoV-2, the architecture
and subcellular location of virus replication sites, the effects
of infection on cell morphology and the timings of each of
these steps [16,17]. For example, fluorescence microscopy
revealed that lentiviruses pseudotyped with SARS-CoV-2
spike glycoprotein can take advantage of clathrin-mediated
endocytosis pathways, where ubiquitous cathepsins take the
place of TMPRSS2 (transmembrane protease serine 2) and
prime the spike glycoprotein for entry within endosomes
[13]. Fluorescence microscopy imaging had also shed light on
other biological properties such as the membrane fusion
activity of the spike glycoprotein, subcellular localization of
viral proteins and inhibitor activity [10,18,19].
Complementary light and electron microscopy modal-
ities, such as cryo-CLEM (cryo-correlative light and electron
microscopy), have been applied to multiple viruses to gain
an understanding of virus life cycles at the lower end of the
resolution spectrum. Application of these modalities to
SARS-CoV-2 allowed rapid identification, tracking of infec-
tion within the cell, including co-localization with cellular
components, and ultrastructural characterization of larger
virus-associated assemblies (such as replication sites). This
type of information is necessary, not only to provide biologi-
cal context but also to gain an understanding that can be
leveraged in the development of antiviral approaches.4. The cryo-EM revolution—impact on
SARS-CoV-2 imaging
What sets the imaging and visualization of SARS-CoV-2 apart
from work done on previous epidemics is the astonishing
amount of high-resolution structural information that was
gleaned and the pace at which it was delivered. This was
made possible largely by transformative technological
advances in cryo-EM (reviewed in [1–3]), and by an unprece-
dented mobilization of the scientific enterprise towards
COVID-19-related research across public and private sectors.
The majority of the cryo-EM-derived structural information
on SARS-CoV-2 has come from image reconstructions deter-
mined by single-particle averaging (SPA). In SPA, thousands,
or even millions, of images of a protein or macromolecular
assembly in different orientations, but ideally in identical
conformations, are extracted from cryo-EM micrographs,
classified, aligned and then averaged to calculate a three-
dimensional structure. The power of this averaging process
greatly reduces the high background noise present in cryo-




Figure 3. A technological revolution in cryo-EM has opened new imaging frontiers. (a) Cryo-EM map of stabilized trimeric spike ectodomain (EMD-21375) fitted
with its corresponding atomic model (PDB 6VSB). Inset shows a closer view of the correspondence between the map and the model. N-terminal domain, blue: RBD,
purple, C-terminal domain, green; fusion peptide, red; HR1, yellow. (b) Cryo-EM map of the apo RNA-dependent RNA polymerase (EMD-11007) fitted with its
corresponding atomic model (PDB 6YYT). Remdesivir is shown in purple, positioned at the end of the RNA product. Its position is based on the alignment of
a remdesivir-bound structure (PDB 7BV2) with the apo model. A clipped perspective of the remdesivir binding site is highlighted in the inset. nsp7, blue;






low scattering potential and therefore low inherent contrast of
biological material, compounded by sample movement and
radiation damage caused by the microscope’s electron beam.
Cryo-EM has existed for decades as a structural technique,
but more recent advances have taken the field to a state where
near-atomic resolutions are readily achievable. Maximum like-
lihood statistical algorithms, as implemented for example in
the RELION software package [20], greatly improve the align-
ment accuracy, and hence the effective resolution, of SPA
image reconstruction. However, this process is computation-
ally expensive. Computation and data storage requirements
that would have been prohibitive even 10 years ago have
recently become tractable through more affordable data sto-
rage, GPU (graphics processing unit)-based parallelization
and the development of faster CPUs (central processing
units). In parallel, the introduction of direct electron detectors,
based on the principles behind the active-pixel CMOS (comp-
lementary metal-oxide-semiconductor) sensors used in
consumer digital cameras, has significantly reduced detector
noise and allowed for the acquisition of movies rather than
still images [21]. With data acquired as a set of movies, some
of the obstacles to high-resolution reconstructions, such as
blurring, can be overcome with computational approaches
including motion-correction algorithms [22]. Together these
advances, along with improved sample preparation work-
flows and hardware, have dramatically improved the
capability of cryo-EM image reconstruction by SPA. As a
result, resolutions comparable to those achieved in X-ray crys-
tallography can now routinely be achieved by cryo-EM. The
key advantage of cryo-EM over crystallography, however, is
that cryo-EM can be used to determine structures of a wide
variety of macromolecules that cannot be readily crystallized
because they are too large, too flexible, insufficiently soluble
(for example because they contain transmembrane domains
or lipid anchors) or simply because they are not available in
sufficient quantity or purity.4.1. The SARS-CoV-2 spike structure
The cumulative technological advances in multiple fields of
structure determination mean that within little over a year ofthe outbreak, structures have been determined of nearly all of
the constituent proteins in SARS-CoV-2 at resolutions sufficient
to allow atomic models to be built [23]. Arguably, the best
example of the speed at which structural biology, and cryo-
EM in particular, can now operate is illustrated by structures
of the spike (S) glycoprotein of SARS-CoV-2. In March 2020,
only a few months after the sequencing of the new virus,
McLellan and colleagues [24] reported a cryo-EM structure of
the soluble ectodomain of S in a stabilized trimeric prefusion
conformation, determined by SPA to 3.5-Å resolution
(figure 3a). Additional cryo-EM structures of the spike trimer
quickly followed (for example, [25–29]), including those in
complex with neutralizing antibody fragments [30] or other
binding partners, at a pace that would not have been possible
using crystallographyorother previouslyavailable approaches.
To date, there are well over 100 cryo-EM structures of the spike
or its subcomponents [31], and the highest resolution structure
currently available was determined to a resolution of 2.4 Å,
which is at least on par with the average resolution of crystal
structures of similarly sized molecules [32].
S is the single most important antigen on the virion sur-
face and is the primary target of most neutralizing
antibodies against SARS-CoV-2 [33]. Consequently, S was
the expressed antigen selected for the first wave of SARS-
CoV-2 vaccines, including those from Pfizer/BioNTech,
Moderna and Oxford–AstraZeneca. Several of the S protein
constructs used for cryo-EM structure determination contain
various stabilizing mutations, most notably proline substi-
tutions at residues 986 and 987, which also help preserve S
in the pre-fusion conformation [24,26,29,32,34]. Previous
structural and immunological studies on spike proteins
from other coronaviruses have shown that such stabilizing
mutations can result in improved expression stability and
immunogenicity [35]. This previous work was fortuitous
because knowledge of these mutations could be directly
and rapidly applied to SARS-CoV-2 vaccine formulations
[29,36], highlighting how in this case structural biology and
vaccinology mutually benefitted each other. The spike struc-
tures have also served as excellent platforms for the analysis
and prediction of the effects of any point mutations acquired





5the rapid turnaround in cryo-EM structure determination
means that spike structures can continue to be determined
to address specific contexts, for example with antibodies or
inhibitors bound, and thus continue to inform treatment
and prevention strategies.
4.2. The RNA polymerase structure
SARS-CoV-2 relies on an RNA-dependent RNA polymerase
(RdRp) to replicate and transcribe its positive-stranded
RNA genome. Viral RNA polymerases have historically
proven to be attractive drug targets. Various small molecules
have been identified that inhibit specific viral RNA poly-
merases without affecting our essential cellular RNA
polymerases. AZT (30-azido-30-deoxythymidine) which inhi-
bits the reverse transcriptase of HIV (a type of RNA
polymerase), paved the way for the successful clinical sup-
pression of chronic HIV infection we have achieved today
[39]. The cure for hepatitis C virus (HCV) developed by
Gilead Sciences, one of the pharmaceutical industry’s most
notable recent successes in the treatment of infectious dis-
eases, includes the use of an HCV RdRp inhibitor [40,41].
The SARS-CoV-2 RdRp was, therefore, immediately ident-
ified as one of the most important targets for structure-based
drug discovery. With a molecular mass under 150 kDa, the
SARS-CoV-2 RdRp would until recently have been too small
to image by cryo-EM. With current technology, however, two
groups were able to independently determine cryo-EM struc-
tures of the SARS-CoV-2 RdRp with an RNA template-product
complex bound at 2.9 Å resolution by early 2020 (figure 3b)
[42,43]. The structure revealed the active site architecture and
served as the ideal platform to accelerate the search for small
molecule inhibitors of RdRp activity. Remdesivir, originally
developed by Gilead as a potential treatment for RNA viruses
and used in clinical trials against Ebola virus [44], became the
first treatment for COVID-19 requiring hospitalization to be
approved by the U.S. Food and Drug Administration in October
2020 [45,46]. Shortly afterwards, cryo-EM structures of SARS-
CoV-2 RdRp with remdesivir bound in the active site showed
how the incorporation of remdesivir by the RdRp into nascent
RNA products blocks translocation of the transcript and thereby
stalling transcription (figure 3b) [47,48]. This example illustrates
how the availability of high-resolution target structures allows
not only structure-based drug design but also elucidation of
drugmechanisms, which in turn allows for future improvement
of specificity and function.
4.3. Cryo-electron tomography of intact virions
Although cryo-EM structures of soluble purified recombinant
spike proteins were rapidly determined by SPA, visualizing
the structure and distribution of S trimer in the context of
intact virions required a different approach. Cryo-EM struc-
ture determination by SPA relies on averaging two-
dimensional images of many highly similar copies of a
macromolecule. But larger biological assemblies tend to be
more structurally heterogeneous, due to the intrinsic flexi-
bility of their protein, lipid or nucleic acid constituents. For
example, no two mitochondria, bacterial flagella or nuclear
pores are exactly identical. Similarly, many viruses, including
SARS-CoV-2, have intrinsically heterogeneous structures.
Because each SARS-CoV-2 virion has a slightly different
shape and spike distribution, structure determination by
SPA is not feasible. However, asymmetric assemblies can bevisualized by another EM-based approach: tomography.
Tomographic reconstruction of cryo-EM micrographs taken
of the same region of interest with the sample tilted through
a series of angles results in a three-dimensional volume (tomo-
gram) that can then be analysed. Recent advances in image
processing algorithms for cryo-electron tomography (cryo-
ET) have improved image alignment accuracy and allowed
for averaging of repeating objects within a volume reconstruc-
tion, a process analogous to SPA known as STA [49,50]. These
advances have allowed for STA reconstructions of macromol-
ecules found within large asymmetric assemblies to be
determined to remarkably high resolutions in some cases (3.4
Å for an HIV capsid structure, for example [51,52]), although
subnanometre resolutions are still not routine.
Leveraging the improved technologies described above,
cryo-ET image reconstructions yielded exquisitely detailed
structures of intact SARS-CoV-2 virions. Subtomogram
averages of the spike trimers within these reconstructions
were determined to subnanometre resolutions (figure 4a,b)
[53–56]. Tomography combined with STA advantageously
not only provides the protein structure but also the protein
distribution, and the SARS-CoV-2 tomograms reveal the vary-
ing orientations and distributions of spike trimers on the virion
surface, in addition to ultrastructural information on ribonu-
cleoprotein assemblies within the virus [55]. Analysis of the
tomograms showed that the spike trimers were more flexible
than expected, with multiple hinge points resulting in various
tilt angles relative to the lipid membrane [54,56]. Some trimers
were also seen to adopt the postfusion conformation rather than
the prefusion conformation, suggesting premature triggering
of the metastable glycoprotein [54]. The presence of the postfu-
sion trimer has clinical implications, not only because the
prefusion state is needed for the virion to be infectious but
also because different antigenic epitopes are exposed in the
pre- and postfusion conformations.
Cryo-ET has also been used to image SARS-CoV-2 virions
in situ, inside infected cells. Frozen vitrified cells were milled
down to 200 nm-thick lamella using a focused ion beam (FIB)
to generate a sample thin enough to be penetrated by an elec-
tron beam. Viruses were then imaged within the subcellular
compartments associated with viral replication [53]. Individ-
ual viral RNAs with branched secondary structures were
observed and viral proteins were found at sites with
increased membrane curvature in the cryo-ET reconstruc-
tions, representing nascent virus particles captured at
intermediate assembly steps (figure 4c) [53]. Hence, these
types of cryo-ET visualizations have provided invaluable
mechanistic insights on vital processes in the life cycle of
SARS-CoV-2.5. X-ray crystallography
The proportion of cryo-EM structures being determined at
resolutions sufficient to support drug design (approx. 3 Å)
is increasing but remains a minority. Thus, most structure-
guided drug discovery efforts continue to rely on crystallo-
graphic structure determination. Using crystal structures to
help identify small molecules targeting SARS-CoV-2 proteins
has been an active and productive area of research. Crystal
structures of the proteases from HIV and HCV contributed
to the development of antiviral protease inhibitors. In combi-
nation with some of the polymerase inhibitors mentioned
(b)(a)
(c)
Figure 4. Cryo-electron tomography (cryo-ET) allows visualization in situ. (a) Three-dimensional volume rendering of a single virion derived from cryo-ET. The spike
glycoprotein (purple) and viral ribonucleoprotein complexes (cyan) are subtomogram averages placed at their corresponding locations in the tomogram with vRNP
orientations randomized. This panel is adapted from ref. [53] and licensed under CC BY 4.0. To view a copy of this license, visit https://creativecommons.org/licenses/
by/4.0/. (b) Subtomogram averages of spike protein from the surface of virions. From left to right: closed conformation (EMD-11494), one RBD up (EMD-11495), two
RBDs up (EMD-11496). RBDs in the up conformation are indicated by arrows. The position of the membrane relative to the glycoprotein is indicated by the double
grey lines. (c) A tomographic slice showing SARS-CoV-2 budding events at ER–Golgi intermediate compartment membranes in VeroE6 cells (EMD-11863) with







above, protease inhibitors are essential components of current
treatments against HIV and HCV. Crystal structures of the
papain-like protease (PLpro) and the main protease Mpro
(also known as 3CLpro) from SARS-CoV-2 have been deter-
mined, including some in complex with candidate
inhibitors (figure 5a,b) [57–61]. These structures provide a
powerful basis for the design of SARS-CoV-2 protease inhibi-
tors. This structure-based design strategy remains one of our
best hopes for developing an effective pharmaceutical
treatment for COVID-19.
In addition to the protease structures, landmark struc-
tures of the spike receptor-binding domain (RBD) were
determined by X-ray crystallography. The RBD is the region
of the S protein that recognizes and binds the host cell,
through the ACE2 (angiotensin-converting enzyme 2) recep-
tor [62]. Many neutralizing antibodies halt infection by
preventing receptor binding. Several of the SARS-CoV-2 var-
iants of concern contain mutations in the RBD, most notably
E484K, that increase ACE2 binding affinity or decrease anti-
body binding affinities (or both) [63,64]. The crystal
structures of RBD bound to a soluble fragment of ACE2
are, therefore, some of the most important structures for
understanding how SARS-CoV-2 recognizes host cells and
how mutations in new virus isolates are likely affect this rec-
ognition (figure 5c) [65–67]. Several crystal structures of the
RBD with various mutations bound to neutralizing antibody
fragments are also available [30]. Together, the crystalstructures of SARS-CoV-2 proteins paint a picture of the
sites of vulnerability within the virus, and the extent to
which they are conserved in different isolates or variants.
This information can be used to develop therapeutics such
as monoclonal antibodies or immunogens that are effective
against a specific variant or set of variants.6. Outlook
The spread of SARS-CoV-2, accelerated by global intercon-
nectedness in our transport and trade links, has taken a
calamitous toll and changed the way we live. However, the
timing of the outbreak was fortuitous in that it followed tech-
nological breakthroughs in vaccinology and structural
biology of a rare magnitude. These breakthroughs allowed
us to visualize how SARS-CoV-2 interacts with cellular com-
ponents in greater detail and at a faster pace than would have
been possible even only a few years earlier. High-resolution
imaging of SARS-CoV-2 has powerfully catalysed efforts to
develop vaccines and therapeutics, giving structural studies
a central role in enabling delivery of new COVID-19 vaccines
and therapies with unprecedented speed. Here, we have
reviewed the principal approaches that have been applied
to visualize SARS-CoV-2, the structures they generated, and
why they were important. Recent advances, particularly in









Figure 5. Crystal structures still provide the most detailed protein structures. (a) A cartoon representation of the crystal structure of the papain-like protease (PLpro)
from nsp3 of SARS-CoV-2 (PDB 6WZU) with red spheres indicating the residues of the catalytic triad and the prototypic ‘thumb–palm–fingers’ architecture annotated
in blue, teal and green. Three different inhibitors that bind to the same pocket are shown in the insets (PDB 7JIR, 7JIT, 7JIW). (b) The crystal structure of the SARS-
CoV-2 Mpro (nsp5) homodimer bound to the 11b inhibitor in teal (PDB 6M0 K). The inset shows how density for the inhibitor can be observed in the crystallographic
map. (c) Cartoon representations of the SARS-CoV-2 receptor binding domain (RBD; blue) bound to three different ligands. From top to bottom: ACE2 (sea green),






biology, making many previously intractable targets amen-
able to molecular-level visualization. The uses and imaging
power of the techniques described here will continue to
grow, yielding invaluable mechanistic insights on vital
processes in the life cycle of SARS-CoV-2 and other viruses.
Another trend that can be expected going forward is an
increase in the number of integrative multiscale imaging
studies that combine different approaches to obtain a more
complete picture of a biological process. Cryo-EM and cryo-
ET imaging fill a gap in the resolution spectrum of imaging
modalities. Cryo-ET allows imaging of intact biological
assemblies in situ, cryo-EM allows more detailed visualized
of macromolecule assemblies, and the resulting structures
from both techniques are constantly improving in resolution
due to ongoing developments in the field. Flanking these
approaches, light microscopy allows us to explore the time
dimension and probe subcellular localization of multiple
components using fluorescent markers at lower resolution
scales. A current limitation of light microscopy is that the
timescales are still relatively short compared to the timescale
of infection. While this means it is difficult to definitively link
characteristics of a tracked virion to observations later in
infection, improvements in both length and resolution ofsuch imaging may someday make this possible. For appli-
cations requiring the highest resolution, such as structure-
based drug design, X-ray crystallography remains the gold
standard, but nuclear magnetic resonance (NMR), a powerful
technique for identifying binding interfaces and measuring
protein dynamics, also has the potential to make future con-
tributions [68]. A beautiful example of multiscale imaging
applied to SARS-CoV-2 is the study by Bartenschlager and
colleagues [16] combining fluorescence microscopy, TEM,
SEM and cryo-ET image reconstruction to visualize the ultra-
structural changes in cellular structures induced by SARS-
CoV-2 infection. The imaging work carried out so far on
SARS-CoV-2 has already yielded an exquisitely detailed pic-
ture of the virus and its interactions with the host [69,70].
Further integrative imaging studies are still needed, however,
in order to improve our understanding of the SARS-CoV-2
life cycle at the molecular level.
The scientific community’s exceptional mobilization on
SARS-CoV-2 research and the confluence of technological
advances in multiple areas, particularly electron microscopy,
have led to progress in visualization of SARS-CoV-2 at a
pace that exceeded all expectations. Imaging studies of
SARS-CoV-2 have informed vaccine design and helped
royalsocietypublishing
8identify new treatment strategies. The momentum gathered in
this fieldmust be sustained ifwewant to control this pandemic
and treat its aftermath. At the same time, we need further
method development in electron microscopy and other areas
of structural biology to continue at a full pace so that we are
even better prepared for future outbreaks. While the emer-
gence of new viruses is inevitable, if we continue on this
trajectory of technological progress and prioritized resourcing .of virus research, we will be better positioned to deal with
future epidemics.
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